help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-1518
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/2/928    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sorrentino, R.
Right arrow Articles by Portella, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sorrentino, R.
Right arrow Articles by Portella, G.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
Medline Plus Health Information
*Thyroid Cancer
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 2 928-935
Copyright © 2005 by The Endocrine Society

Aurora B Overexpression Associates with the Thyroid Carcinoma Undifferentiated Phenotype and Is Required for Thyroid Carcinoma Cell Proliferation

Rosanna Sorrentino, Silvana Libertini, Pier Lorenzo Pallante, Giancarlo Troncone, Lucio Palombini, Vassilios Bavetsias, Daniela Spalletti-Cernia, Paolo Laccetti, Spiros Linardopoulos, Paolo Chieffi, Alfredo Fusco and Giuseppe Portella

Dipartimenti di Biologia e Patologia Cellulare e Molecolare (R.S., S.Lib., P.L.P., D.S.-C., A.F., G.P.), Scienze Biomorfologiche e Funzionali-Istituto di Anatomia Patologica (G.T., L.P.), and Chimica Biologica (P.L.), Università Federico II, 80131 Naples, Italy; Cancer Research U.K. Centre for Cancer Therapeutics (V.B., S.Lin.), Institute of Cancer Research 15, Belmont, Sutton, Surrey SM2 5NG, United Kingdom; The Breakthrough Breast Cancer Research Centre (S.Lin.), Institute of Cancer Research, London SW3 6JB, United Kingdom; and Dipartimento di Medicina Sperimentale (P.C.), II Università di Napoli, 80138 Naples, Italy

Address all correspondence and requests for reprints to: Giuseppe Portella, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Facoltà di Medicina e Chirurgia di Napoli, Università Federico II, via S. Pansini 5, 80131 Napoli, Italy. E-mail: portella{at}unina.it

Alterations in chromosome number (aneuploidy) are common in human neoplasias. Loss of mitotic regulation is believed to induce aneuploidy in cancer cells and act as a driving force during the malignant progression. The serine/theronine protein kinases of aurora family genes play a critical role in the regulation of key cell cycle processes. Aurora B mediates chromosome segregation by ensuring orientation of sister chromatids and overexpression of Aurora B in diploid human cells NHDF (normal human diploid fibroblast) induces multinuclearity.

We analyzed Aurora B expression in human thyroid carcinomas. Cell lines originating from different histotypes showed an increase in Aurora B expression. Immunohistochemical analysis of archive samples showed a high expression of Aurora B in anaplastic thyroid carcinomas; conversely, Aurora B expression was not detectable in normal thyroid tissue. Real-time PCR analysis confirmed a strong expression of Aurora B in anaplastic thyroid carcinomas.

The block of Aurora B expression induced by RNA interference or by using an inhibitor of Aurora kinase activity significantly reduced the growth of thyroid anaplastic carcinoma cells.




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
Y. Arlot-Bonnemains, E. Baldini, B. Martin, J.-G. Delcros, M. Toller, F. Curcio, F. S Ambesi-Impiombato, M. D'Armiento, and S. Ulisse
Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines
Endocr. Relat. Cancer, June 1, 2008; 15(2): 559 - 568.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
O. Gautschi, J. Heighway, P. C. Mack, P. R. Purnell, P. N. Lara Jr., and D. R. Gandara
Aurora Kinases as Anticancer Drug Targets
Clin. Cancer Res., March 15, 2008; 14(6): 1639 - 1648.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
F. Chan, C. Sun, M. Perumal, Q.-D. Nguyen, V. Bavetsias, E. McDonald, V. Martins, N. E. Wilsher, F. I. Raynaud, M. Valenti, et al.
Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity
Mol. Cancer Ther., December 1, 2007; 6(12): 3147 - 3157.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
P. Carpinelli, R. Ceruti, M. L. Giorgini, P. Cappella, L. Gianellini, V. Croci, A. Degrassi, G. Texido, M. Rocchetti, P. Vianello, et al.
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
Mol. Cancer Ther., December 1, 2007; 6(12): 3158 - 3168.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
S. M. Wiseman, H. Masoudi, P. Niblock, D. Turbin, A. Rajput, J. Hay, S. Bugis, D. Filipenko, D. Huntsman, and B. Gilks
Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment
Ann. Surg. Oncol., February 1, 2007; 14(2): 719 - 729.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
W. F Zeng, K. Navaratne, R. A Prayson, and R. J Weil
Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme
J. Clin. Pathol., February 1, 2007; 60(2): 218 - 221.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. Vischioni, J. J. Oudejans, W. Vos, J. A. Rodriguez, and G. Giaccone
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients.
Mol. Cancer Ther., November 1, 2006; 5(11): 2905 - 2913.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
Y. Li, G. D. Kao, B. A. Garcia, J. Shabanowitz, D. F. Hunt, J. Qin, C. Phelan, and M. A. Lazar
A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity
Genes & Dev., September 15, 2006; 20(18): 2566 - 2579.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Y. Shi, M. Zou, K. Collison, E. Y. Baitei, Z. Al-Makhalafi, N. R. Farid, and F. A. Al-Mohanna
Ribonucleic Acid Interference Targeting S100A4 (Mts1) Suppresses Tumor Growth and Metastasis of Anaplastic Thyroid Carcinoma in a Mouse Model
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2373 - 2379.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Y. E. Nikiforov
Anaplastic Carcinoma of the Thyroid--Will Aurora B Light a Path for Treatment?
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1243 - 1245.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society